Clovis Oncology, Inc. (CLVS) Financial Statements (2024 and earlier)

Company Profile

Business Address 5500 FLATIRON PARKWAY
BOULDER, CO 80301
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 143,428240,229296,659520,146563,731266,183
Cash and cash equivalents 143,428240,229161,833221,876464,198216,186
Short-term investments   134,826298,27099,53349,997
Receivables 26,86826,51120,56212,8896,181121
Inventory, net of allowances, customer advances and progress billings 13,68830,71426,51927,07227,508 
Inventory 13,68830,71426,51927,07227,508 
Prepaid expense 2,3974,2453,8813,5791,5596,427
Other current assets 11,7069,13018,8478,6137,5006,679
Other undisclosed current assets     20,461 
Total current assets: 198,087310,829366,468572,299626,940279,410
Noncurrent Assets
Inventory, Noncurrent 109,848104,12398,053113,908  
Property, plant and equipment 6,55412,08515,28726,5244,0074,440
Intangible assets, net (including goodwill) 123,445128,817125,994115,00484,77878,239
Goodwill 63,07463,07463,07463,07465,21757,192
Intangible assets, net (excluding goodwill) 60,37165,74362,92051,93019,56121,047
Regulated entity, other noncurrent assets 6,510     
Other noncurrent assets 15,79019,26223,31123,47519,5052,468
Other undisclosed noncurrent assets 12,59930,43840,49112,350  
Total noncurrent assets: 274,746294,725303,136291,261108,29085,147
TOTAL ASSETS: 472,833605,554669,604863,560735,230364,557
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 78,17971,90074,46596,07341,03030,399
Accounts payable 27,30826,69232,23728,51715,14710,912
Accrued liabilities 50,87145,20842,22867,55625,88319,487
Debt  64,198    
Other undisclosed current liabilities 47,03548,83058,61929,67640,48735,198
Total current liabilities: 125,214184,928133,084125,74981,51765,597
Noncurrent Liabilities
Long-term debt and lease obligation 436,772434,846644,751575,470282,406281,126
Long-term debt, excluding current maturities 436,772434,846644,751575,470282,406281,126
Liabilities, other than long-term debt, including:  1,9711,55615,8723,6711,406
Deferred revenue and credits3,6711,406
Other undisclosed liabilities, other than long-term debt  1,9711,55615,872  
Other undisclosed noncurrent liabilities 189,687142,55764,470  20,062
Total noncurrent liabilities: 626,459579,374710,777591,342286,077302,594
Total liabilities: 751,673764,302843,861717,091367,594368,191
Equity
Equity, attributable to parent (278,840)(158,748)(174,257)146,469367,636(3,634)
Common stock 12910455535139
Additional paid in capital 2,641,7122,498,1792,114,0682,034,1421,887,1981,174,950
Accumulated other comprehensive loss (43,430)(44,304)(44,865)(44,634)(42,173)(47,580)
Accumulated deficit (2,877,251)(2,612,727)(2,243,515)(1,843,092)(1,477,440)(1,131,043)
Total equity: (278,840)(158,748)(174,257)146,469367,636(3,634)
TOTAL LIABILITIES AND EQUITY: 472,833605,554669,604863,560735,230364,557

Income Statement (P&L) ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 148,757164,522143,00695,38855,51178
Revenue, net55,51178
Cost of revenue (41,030)   (1,486)(70)
Cost of goods and services sold     (1,486)(70)
Gross profit: 107,727164,522143,00695,38854,0258
Operating expenses (333,494)(466,710)(519,752)(429,202)(293,142)(372,811)
Other undisclosed operating income     1,48670
Operating loss: (225,767)(302,188)(376,746)(333,814)(237,631)(372,733)
Nonoperating expense (39,161)(67,571)(21,880)(33,587)(112,344)(8,438)
Other nonoperating income 4441,3616,3427,9173,643633
Interest and debt expense (34,103)(35,075)18,480(2,870)(10,428)(8,491)
Loss from continuing operations before equity method investments, income taxes: (299,031)(404,834)(380,146)(370,271)(360,403)(389,662)
Other undisclosed income (loss) from continuing operations before income taxes 34,10335,075(18,480)2,87010,4288,491
Loss from continuing operations before income taxes: (264,928)(369,759)(398,626)(367,401)(349,975)(381,171)
Income tax expense (benefit) 404547(1,798)(608)3,57832,034
Loss from continuing operations: (264,524)(369,212)(400,424)(368,009)(346,397)(349,137)
Loss before gain (loss) on sale of properties:(264,524)(369,212)(400,424)(368,009)(346,397)(349,137)
Net loss available to common stockholders, diluted: (264,524)(369,212)(400,424)(368,009)(346,397)(349,137)

Comprehensive Income ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss: (264,524)(369,212)(400,424)(368,009)(346,397)(349,137)
Other comprehensive income (loss) 874561(231)(2,461)5,407(120)
Comprehensive loss, net of tax, attributable to parent: (263,650)(368,651)(400,655)(370,470)(340,990)(349,257)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: